| Madhav Lavu, MD | |
|
825 2nd Ave Ste B1, Bowling Green, KY 42101-1790 | |
| (270) 782-0151 | |
| (270) 782-7528 |
| Full Name | Madhav Lavu |
|---|---|
| Gender | Male |
| Speciality | Cardiac Electrophysiology |
| Experience | 22 Years |
| Location | 825 2nd Ave Ste B1, Bowling Green, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447459193 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | TP769 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Fargo | Fargo, ND | Hospital |
| Perham Health | Perham, MN | Hospital |
| Altru Hospital | Grand forks, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Clinic North | 4284546151 | 84 |
| Sanford Medical Center Fargo | 8426967803 | 1094 |
News Archive
Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company, and Ipsen, a global biotechnology specialty care group, announced today that the two companies have entered into an exclusive research collaboration agreement to leverage their expertise in Dicer Substrate siRNA (DsiRNA) research and peptide engineering. The companies will develop novel conjugates of Dicerna's DsiRNA molecules and Ipsen's peptide targeting vectors in the therapeutic areas of oncology and endocrinology.
Würzburg neurologists have discovered an antibody that is involved in triggering certain forms of neuropathies. This discovery also allowed them to show a way to treat these diseases successfully.
A ‘polypill' made up of a combination of drugs could extend the lives of thousands of patients with coronary heart disease, say researchers at The University of Nottingham.
Cancer-related fatigue is often a major problem for cancer patients, beginning at diagnosis, during treatment and after completing therapy. Researchers at Mayo Clinic and the North Central Cancer Treatment Group recently completed a study testing methylphenidate in the treatment of cancer-related fatigue and found that, while it did not improve fatigue for a broad group of patients, the data did not rule out a benefit for those with stage III/IV cancer.
CANCER RESEARCH UK-funded scientists have discovered that skin cancer can spread to the lungs when a gene in an important cell communication pathway is blocked. The research is published in Cancer Cell.
› Verified 2 days ago
| Entity Name | Sanford Clinic North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241351 PECOS PAC ID: 4284546151 Enrollment ID: O20031112000221 |
News Archive
Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company, and Ipsen, a global biotechnology specialty care group, announced today that the two companies have entered into an exclusive research collaboration agreement to leverage their expertise in Dicer Substrate siRNA (DsiRNA) research and peptide engineering. The companies will develop novel conjugates of Dicerna's DsiRNA molecules and Ipsen's peptide targeting vectors in the therapeutic areas of oncology and endocrinology.
Würzburg neurologists have discovered an antibody that is involved in triggering certain forms of neuropathies. This discovery also allowed them to show a way to treat these diseases successfully.
A ‘polypill' made up of a combination of drugs could extend the lives of thousands of patients with coronary heart disease, say researchers at The University of Nottingham.
Cancer-related fatigue is often a major problem for cancer patients, beginning at diagnosis, during treatment and after completing therapy. Researchers at Mayo Clinic and the North Central Cancer Treatment Group recently completed a study testing methylphenidate in the treatment of cancer-related fatigue and found that, while it did not improve fatigue for a broad group of patients, the data did not rule out a benefit for those with stage III/IV cancer.
CANCER RESEARCH UK-funded scientists have discovered that skin cancer can spread to the lungs when a gene in an important cell communication pathway is blocked. The research is published in Cancer Cell.
› Verified 2 days ago
| Entity Name | Sanford Medical Center Fargo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184917924 PECOS PAC ID: 8426967803 Enrollment ID: O20110331000495 |
News Archive
Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company, and Ipsen, a global biotechnology specialty care group, announced today that the two companies have entered into an exclusive research collaboration agreement to leverage their expertise in Dicer Substrate siRNA (DsiRNA) research and peptide engineering. The companies will develop novel conjugates of Dicerna's DsiRNA molecules and Ipsen's peptide targeting vectors in the therapeutic areas of oncology and endocrinology.
Würzburg neurologists have discovered an antibody that is involved in triggering certain forms of neuropathies. This discovery also allowed them to show a way to treat these diseases successfully.
A ‘polypill' made up of a combination of drugs could extend the lives of thousands of patients with coronary heart disease, say researchers at The University of Nottingham.
Cancer-related fatigue is often a major problem for cancer patients, beginning at diagnosis, during treatment and after completing therapy. Researchers at Mayo Clinic and the North Central Cancer Treatment Group recently completed a study testing methylphenidate in the treatment of cancer-related fatigue and found that, while it did not improve fatigue for a broad group of patients, the data did not rule out a benefit for those with stage III/IV cancer.
CANCER RESEARCH UK-funded scientists have discovered that skin cancer can spread to the lungs when a gene in an important cell communication pathway is blocked. The research is published in Cancer Cell.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Madhav Lavu, MD Po Box 2168, Fargo, ND 58107-2168 Ph: (701) 417-2575 | Madhav Lavu, MD 825 2nd Ave Ste B1, Bowling Green, KY 42101-1790 Ph: (270) 782-0151 |
News Archive
Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company, and Ipsen, a global biotechnology specialty care group, announced today that the two companies have entered into an exclusive research collaboration agreement to leverage their expertise in Dicer Substrate siRNA (DsiRNA) research and peptide engineering. The companies will develop novel conjugates of Dicerna's DsiRNA molecules and Ipsen's peptide targeting vectors in the therapeutic areas of oncology and endocrinology.
Würzburg neurologists have discovered an antibody that is involved in triggering certain forms of neuropathies. This discovery also allowed them to show a way to treat these diseases successfully.
A ‘polypill' made up of a combination of drugs could extend the lives of thousands of patients with coronary heart disease, say researchers at The University of Nottingham.
Cancer-related fatigue is often a major problem for cancer patients, beginning at diagnosis, during treatment and after completing therapy. Researchers at Mayo Clinic and the North Central Cancer Treatment Group recently completed a study testing methylphenidate in the treatment of cancer-related fatigue and found that, while it did not improve fatigue for a broad group of patients, the data did not rule out a benefit for those with stage III/IV cancer.
CANCER RESEARCH UK-funded scientists have discovered that skin cancer can spread to the lungs when a gene in an important cell communication pathway is blocked. The research is published in Cancer Cell.
› Verified 2 days ago
Rodney T. Steff, DO Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 421 Us 31w Byp, Bowling Green, KY 42101 Phone: 270-782-0151 | |
Dr. Daniel R Long, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 250 Park St, Bowling Green, KY 42101 Phone: 270-745-1000 | |
Dr. Rance Wentworth, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 201 Park St, Bowling Green, KY 42101 Phone: 270-781-5111 Fax: 270-780-0462 | |
Pinky Dalal Gaba, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 427 Us 31w Byp, Bowling Green, KY 42101 Phone: 270-796-8800 Fax: 270-796-9328 | |
Ms. Uma Akkineni, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 250 Park St, Bowling Green, KY 42101 Phone: 270-796-6540 Fax: 270-796-6576 | |
Mohammed Kazimuddin, MD FACC FSCAI Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 825 Second Ave, Ste B1, Bowling Green, KY 42101 Phone: 270-782-0151 Fax: 270-782-7528 | |
Ann Scarlet Monardo, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 484 Golden Autumn Way Ste 201, Bowling Green, KY 42103 Phone: 270-393-2759 |